Colorectal Cancer

Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

The FDA accepted a supplemental New Drug Application for tucatinib to treat HER2 colorectal cancer, which could significantly improve outcomes for these patients.

Selpercatinib produced clinically meaningful and durable responses across a variety of tumor types in patients with RET-driven cancers.

Study indicates that a diet high in ultra-processed food is more likely to increase the risk of colorectal cancer in men than it is women.

Therapy shows positive clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in heavily pretreated patients who have a KRASG12C mutation.

Fruquintinib reduced the risk of death in patients with advanced metastatic colorectal cancer by 34% and led to longer overall survival than among those given placebo.

Processed meats and products high in added sugars and low in fiber contribute to weight gain and obesity, which is an established risk factor.

Scientists found that inhibiting certain immune system receptors could treat colon cancer and other diseases of the gastrointestinal tract.

Gamma-delta T-cells undergo a biochemical change that leads them to spur the growth of tumors that previously restricted.

Delayed diagnosis in younger individuals and presentation of advanced disease highlights need for awareness.

The results showed a 38.1% confirmed objective response rate among HER2-positive patients who received tucatinib in combination with trastuzumab.

Analysis shows that the common infection may be a driver of the disease in adults younger than aged 50 years.

Screening participation increased over time, but the increase was smallest among individuals aged 50 to 54.

Nearly 63% of newly diagnosed patients have advanced colorectal cancer, which requires more aggressive treatment and reduces the associated 5-year survival rate.

Capecitabine (Xeloda) is indicated for adjuvant colon cancer, metastatic colorectal cancer, and metastatic breast cancer.

Bevacizumab-maly (Almysys; mAbxience) is the third biosimilar of bevacizumab (Avastin) approved in the United States.

Encorafenib in combination With anti-EGFR monoclonal antibody improves overall survival.

Ramucirumab (Cyramza; Eli Lilly) is FDA-approved for 5 unique cancer indications.

The CAR T-cell therapy CYAD-101 was being evaluated in combination with FOLFOX followed by pembrolizumab (Keytruda) in patients with unresectable metastatic colorectal cancer.

Culturally tailored patient navigation can improve underserved individuals’ health literacy, trust in the health care system, and use of cancer screening tools, study results show.

Commonly used medications may influence responses to checkpoint inhibitors among patients with cancer.

The FDA initially approved regorafenib for chemorefractory metastatic colorectal cancer and unresectable gastrointestinal stromal tumor in 2012.

Study finds that 16.9% of stomach cancers, 11.9% of endometrial cancers, 11.0% of kidney cancers, 9.3% of colon cancers, 8.1% of esophageal cancers, 6.5% of female breast cancers, and 3.9% of urinary bladder cancers were associated with a low level of exercise.

Chemotherapy for colorectal cancer include 5-fluorouracil (5-FU), capecitabine (Xeloda), irinotecan (Camptosar), oxaliplatin (Eloxatin), and trifluridine and tipiracil (Lonsurf).

The majority of treatment-related adverse events (TRAEs) were grade 1-2 in severity, and no patients experienced dose-limiting toxicities during the 28 days following initial treatment.

The combination of cetuximab and encorafenib resulted in a median overall survival of 8.4 months, compared to 5.4 months in the control arm among patients with colorectal cancer.

Umeā University in Sweden finds a connection between the two, due to the intestinal micobiome.

The continued approval for this indication may be subject upon verification and description of clinical benefit in a confirmatory trial.

Patients with microsatellite stable (MSS) colorectal cancer, which represents 95% of all metastatic colorectal cancer cases, are more responsive to checkpoint blockade immunotherapy if the patient’s tumors have not spread to the liver.

New research presented at the ESMO World Congress on Gastrointestinal Cancer suggests the use of antibiotics may increase the risk of colon cancer, especially in individuals under age 50 years.